This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Walker, D. G. Articles by Lavin, M. Search for Related Content PubMed PubMed Citation Articles by Walker, D. G. Articles by Lavin, M.

Homozygous Deletions of the Multiple Tumor Suppressor Gene 1 in the Progression of Human Astrocytomas¹

Department of Surgery, University of Queensland and Queensland Institute of Medical Research, Herston, 4029, Queensland [D. G. W., F. H. T., M. L.], and Neuroscience Research Laboratories, Clinical Neuroscience Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, 3050, Victoria [W. D., E. A. P., A. H. K.], Australia

The multiple tumor suppressor gene 1 (MTS1) located on chromosome 9p has recently been implicated as a candidate tumor suppressor gene in many different tumor types. Cytogenetic analysis and deletion mapping studies have revealed that deletion of chromosome 9p occurs in a significant number of primary human astrocytomas. Using multiplex PCR with primers for exon 2 of MTS1 and for D9S196 from chromosome 9q, we have analyzed 78 primary astrocytic tumors for the deletion of MTS1. After controlling for the contamination of tumor samples with normal cells, homozygous loss of MTS1 was found in 13 of 25 anaplastic astrocytomas (WHO grade III) and in 27 of 46 cases of glioblastomas (WHO grade IV) but in none of seven astrocytomas (WHO grade II). These data suggest that MTS1 is an important tumor suppressor gene in the malignant progression of astrocytomas.

¹ Supported by the National Health and Medical Research Council, the Anti-Cancer Council of Victoria and the Royal Australasian College of Surgeons' Foundation Scholarships.

² To whom requests for reprints should be addressed, at Cancer Research Unit, Queensland Institute of Medical Research, 300 Herston Road, Herston, Brisbane 4029, Australia.

Received 8/26/94. Accepted 11/14/94.

This article has been cited by other articles:

				P. Leuraud, L. Taillandier, J. Medioni, L. Aguirre-Cruz, E. Criniere, Y. Marie, M. Kujas, J.-L. Golmard, A. Duprez, J.-Y. Delattre, et al. Distinct Responses of Xenografted Gliomas to Different Alkylating Agents Are Related to Histology and Genetic Alterations Cancer Res., July 1, 2004; 64(13): 4648 - 4653. [Abstract] [Full Text] [PDF]

				R. Roca, R. M. Kypta, and M. d. M. Vivanco Loss of p16INK4a results in increased glucocorticoid receptor activity during fibrosarcoma development PNAS, March 18, 2003; 100(6): 3113 - 3118. [Abstract] [Full Text] [PDF]

				K. Hoang-Xuan, J. He, S. Huguet, K. Mokhtari, Y. Marie, M. Kujas, P. Leuraud, L. Capelle, J. Y. Delattre, J. Poirier, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression Neurology, October 9, 2001; 57(7): 1278 - 1281. [Abstract] [Full Text] [PDF]

				R. N. Wiltshire, B.K. A. Rasheed, H. S. Friedman, A. H. Friedman, and S. H. Bigner Comparative genetic patterns of glioblastoma multiforme: Potential diagnostic tool for tumor classification Neuro-oncol, July 1, 2000; 2(3): 164 - 173. [Abstract] [PDF]

				H. P. Kourea, I. Orlow, B. W. Scheithauer, C. Cordon-Cardo, and J. M. Woodruff Deletions of the INK4A Gene Occur in Malignant Peripheral Nerve Sheath Tumors but not in Neurofibromas Am. J. Pathol., December 1, 1999; 155(6): 1855 - 1860. [Abstract] [Full Text] [PDF]

				E. P. Xing, Y. Nie, L.-D. Wang, G.-Y. Yang, and C. S. Yang Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China Carcinogenesis, January 1, 1999; 20(1): 77 - 84. [Abstract] [Full Text] [PDF]